Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors

Key points
- To determine whether age/gender-based differences in efficacy exist between bupropion and the selective serotonin reuptake inhibitors for major depressive disorder, we pooled the findings of 10 double-blind studies comparing bupropion with a selective serotonin reuptake inhibitor.
- Men (N=943) and women (N=1179) were divided into three age groups (younger than 40, 40-55, older than 55).
- Of 64 pair-wise comparisons, only one was statistically significant.
- No difference, however, was seen in the degree of resolution of Hamilton Depression Rating Scale Anxiety-Somatization scores (continuous measure) between women treated with bupropion versus a selective serotonin reuptake inhibitor (P=0.114).
Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions
To determine whether age/gender-based differences in efficacy exist between bupropion and the selective serotonin reuptake inhibitors for major depressive disorder, we pooled the findings of 10 double-blind studies comparing bupropion with a selective serotonin reuptake inhibitor.
Men (N=943) and women (N=1179) were divided into three age groups (younger than 40, 40-55, older than 55). Improvement in terms of the 17-item Hamilton Depression Rating Scale, as well as the Bech melancholia, anxiety-somatization, and insomnia factors of the Hamilton Depression Rating Scale was compared between the two treatment groups.
Of 64 pair-wise comparisons, only one was statistically significant. Specifically, more women treated with a selective serotonin reuptake inhibitor experienced a 50% or greater decrease in Hamilton Depression Rating Scale Anxiety-Somatization scores (58.8 versus 63.8%, P=0.0394).
No difference, however, was seen in the degree of resolution of Hamilton Depression Rating Scale Anxiety-Somatization scores (continuous measure) between women treated with bupropion versus a selective serotonin reuptake inhibitor (P=0.114).
Bupropion and the selective serotonin reuptake inhibitors, thus, appear to be equally effective in treating depressive symptoms, as well as anxious/somatic symptoms and insomnia in depression. No gender-related or age-related differences were found except that greater improvement was seen in anxious/somatic symptoms of depression among women during selective serotonin reuptake inhibitor treatment.
This finding could, however, not be replicated when improvement in anxious/somatic symptoms was defined as a continuous measure.
International Clinical Psychopharmacology. 22(4):226-229, July 2007.
Papakostas, George I. a; Kornstein, Susan G. b; Clayton, Anita H. c; Soares, Claudio N. e; Hallett, Lindsay A. a; Krishen, Alok d; Tucker, Vivian L. d
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsHeart risk link to SSRI antidepressants confirmed
Some but not all antidepressant drugs known as SSRIs pose a very small but serious heart risk, say researchers. Citalopram and escitalopram, which fall into this drug group, can trigger a heart rhythm disturbance, a new…
31 January 2013
NewsAntidepressants linked to risk of brain bleeds
People using a common class of antidepressants may have slightly increased odds of suffering bleeding in the brain - though the risk is still very small, researchers reported Wednesday. The antidepressants are known as…
18 October 2012
NewsFor Binge Drinkers, Even Relatively Minor Burn Injuries Can Lead to Serious Complications
A Loyola University Medical Center study has found that binge drinking may slow recovery and increase medical costs for survivors of burn injuries. The study was presented during the 44th Annual Meeting of the American…





